ALK阳性-话题@MedSci

#ALK阳性#

66篇内容 | 1048人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1987523, encodeId=2800198e523a0, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌, objectType=article, longId=100354, objectId=1e69100354f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e69100354f5, replyNumber=0, likeNumber=33, createdTime=2018-04-10, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e69100354f5, moduleTitle=诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e69100354f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987526, encodeId=43dc198e5264c, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者, objectType=article, longId=101275, objectId=d71d1012e5ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d71d1012e5ac, replyNumber=0, likeNumber=34, createdTime=2017-10-05, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d71d1012e5ac, moduleTitle=Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d71d1012e5ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987524, encodeId=a52f198e52445, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌, objectType=article, longId=100784, objectId=52ba100e84d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52ba100e84d9, replyNumber=0, likeNumber=35, createdTime=2017-07-31, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52ba100e84d9, moduleTitle=ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52ba100e84d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987528, encodeId=ee9a198e528b4, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹, objectType=article, longId=111480, objectId=aacf11148072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aacf11148072, replyNumber=0, likeNumber=28, createdTime=2017-10-23, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aacf11148072, moduleTitle=NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aacf11148072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Haematologica：ALK阳性间变性大细胞淋巴瘤的特征是重排ALK基因拷贝数增加, objectType=article, longId=105447, objectId=bba010544edd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bba010544edd, replyNumber=0, likeNumber=43, createdTime=2017-12-30, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bba010544edd, moduleTitle=Haematologica：ALK阳性间变性大细胞淋巴瘤的特征是重排ALK基因拷贝数增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bba010544edd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987521, encodeId=7b6e198e52122, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼, objectType=article, longId=98487, objectId=f82a9848ea1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f82a9848ea1, replyNumber=0, likeNumber=28, createdTime=2017-09-09, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f82a9848ea1, moduleTitle=Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f82a9848ea1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987525, encodeId=03a6198e525b8, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！, objectType=article, longId=101153, objectId=1b50101153e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b50101153e0, replyNumber=0, likeNumber=35, createdTime=2018-05-21, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b50101153e0, moduleTitle=NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b50101153e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987519, encodeId=ad46198e519a6, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格, objectType=article, longId=79315, objectId=590ee9315c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=590ee9315c5, replyNumber=0, likeNumber=30, createdTime=2017-07-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=590ee9315c5, moduleTitle=ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=590ee9315c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987522, encodeId=1657198e52237, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=JCO：Brigatinib二线治疗ALK阳性NSCLC有力量, objectType=article, longId=98708, objectId=105298e082a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=105298e082a, replyNumber=0, likeNumber=33, createdTime=2017-09-02, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=105298e082a, moduleTitle=JCO：Brigatinib二线治疗ALK阳性NSCLC有力量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=105298e082a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987520, encodeId=dea1198e5205a, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, objectType=article, longId=79864, objectId=5769e986481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5769e986481, replyNumber=0, likeNumber=21, createdTime=2017-01-06, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5769e986481, moduleTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5769e986481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987518, encodeId=d823198e518cd, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=2016 加拿大共识：晚期非小细胞肺癌ALK阳性肿瘤抑制发布, objectType=article, longId=78745, objectId=65ade87459b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ade87459b, replyNumber=0, likeNumber=9, createdTime=2017-05-30, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ade87459b, moduleTitle=2016 加拿大共识：晚期非小细胞肺癌ALK阳性肿瘤抑制发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ade87459b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987517, encodeId=3fca198e517b8, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=喜讯！辉瑞口服靶向抗癌药Xalkori（克唑替尼）获英国NICE推荐，一线治疗ALK阳性肺癌, objectType=article, longId=75774, objectId=c8c4e5774d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8c4e5774d2, replyNumber=0, likeNumber=29, createdTime=2017-01-05, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8c4e5774d2, moduleTitle=喜讯！辉瑞口服靶向抗癌药Xalkori（克唑替尼）获英国NICE推荐，一线治疗ALK阳性肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8c4e5774d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987515, encodeId=baaa198e515a2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=患者招募：一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究, objectType=article, longId=61213, objectId=718a6121359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=718a6121359, replyNumber=0, likeNumber=27, createdTime=2016-11-02, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=718a6121359, moduleTitle=患者招募：一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=718a6121359)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987516, encodeId=5704198e516d4, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物, objectType=article, longId=65871, objectId=541e658e142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541e658e142, replyNumber=0, likeNumber=46, createdTime=2016-06-01, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541e658e142, moduleTitle=JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541e658e142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987514, encodeId=4368198e51474, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Lancet Oncol：Alectinib治疗ALK阳性，克唑替尼耐药，非小细胞肺癌患者疗效显著, objectType=article, longId=60861, objectId=be8c6086141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be8c6086141, replyNumber=0, likeNumber=41, createdTime=2016-06-16, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be8c6086141, moduleTitle=Lancet Oncol：Alectinib治疗ALK阳性，克唑替尼耐药，非小细胞肺癌患者疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be8c6086141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987513, encodeId=80e8198e5134a, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=诺华ALK阳性肺癌药物Zykadia色瑞替尼获欧洲批准, objectType=article, longId=50626, objectId=d0625062609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0625062609, replyNumber=0, likeNumber=49, createdTime=2015-06-16, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0625062609, moduleTitle=诺华ALK阳性肺癌药物Zykadia色瑞替尼获欧洲批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0625062609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987512, encodeId=a68a198e512e2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Clin Cancer Res：色瑞替尼对ALK阳性的非小细胞肺癌有显著的抗肿瘤活性, objectType=article, longId=47739, objectId=6fb64e739f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb64e739f8, replyNumber=0, likeNumber=33, createdTime=2015-12-16, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb64e739f8, moduleTitle=Clin Cancer Res：色瑞替尼对ALK阳性的非小细胞肺癌有显著的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fb64e739f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987511, encodeId=b637198e511b2, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=JTO：Alectinib能用于ALK阳性的耐药的非小细胞肺癌脑转移治疗, objectType=article, longId=46481, objectId=83624648114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83624648114, replyNumber=0, likeNumber=28, createdTime=2015-06-17, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83624648114, moduleTitle=JTO：Alectinib能用于ALK阳性的耐药的非小细胞肺癌脑转移治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83624648114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987510, encodeId=0739198e51026, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期, objectType=article, longId=43675, objectId=ea41436e517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea41436e517, replyNumber=0, likeNumber=30, createdTime=2015-04-22, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea41436e517, moduleTitle=NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea41436e517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987509, encodeId=6625198e50905, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理, objectType=article, longId=37519, objectId=234f3e51952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234f3e51952, replyNumber=0, likeNumber=34, createdTime=2014-09-24, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234f3e51952, moduleTitle=CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234f3e51952)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALK阳性

2020-05-29

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌

2018-04-10

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Lancet Oncol：色瑞替尼用于克唑替尼耐药的ALK阳性非小细胞肺癌患者

2017-10-05

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ASCO2017：克唑替尼用于ALK阳性非小细胞肺癌

2017-07-31

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NEJM：ALK阳性非小细胞肺癌“头碰头”研究艾乐替尼更胜一筹

2017-10-23

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Haematologica：ALK阳性间变性大细胞淋巴瘤的特征是重排ALK基因拷贝数增加

2017-12-30

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Lancet：头碰头一线ALK阳性非小细胞肺癌治疗艾乐替尼vs克唑替尼

2017-09-09

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！

2018-05-21

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格

2017-07-19

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

JCO：Brigatinib二线治疗ALK阳性NSCLC有力量

2017-09-02

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS

2017-01-06

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

2016 加拿大共识：晚期非小细胞肺癌ALK阳性肿瘤抑制发布

2017-05-30

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

喜讯！辉瑞口服靶向抗癌药Xalkori（克唑替尼）获英国NICE推荐，一线治疗ALK阳性肺癌

2017-01-05

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

患者招募：一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究

2016-11-02

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

JCO：克唑替尼可以作为ALK阳性非小细胞肺癌一线治疗药物

2016-06-01

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Lancet Oncol：Alectinib治疗ALK阳性，克唑替尼耐药，非小细胞肺癌患者疗效显著

2016-06-16

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

诺华ALK阳性肺癌药物Zykadia色瑞替尼获欧洲批准

2015-06-16

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Clin Cancer Res：色瑞替尼对ALK阳性的非小细胞肺癌有显著的抗肿瘤活性

2015-12-16

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

JTO：Alectinib能用于ALK阳性的耐药的非小细胞肺癌脑转移治疗

2015-06-17

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期

2015-04-22

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

CSMO 2014：刘晓晴谈论ALK阳性NSCLC诊治进展及全程管理

2014-09-24

科室
- - 订阅+
  - 更多科室
工具
服务